CN112402334B - 青稞发酵提取物的应用 - Google Patents
青稞发酵提取物的应用 Download PDFInfo
- Publication number
- CN112402334B CN112402334B CN201910780847.9A CN201910780847A CN112402334B CN 112402334 B CN112402334 B CN 112402334B CN 201910780847 A CN201910780847 A CN 201910780847A CN 112402334 B CN112402334 B CN 112402334B
- Authority
- CN
- China
- Prior art keywords
- highland barley
- skin
- fermentation
- supernatant
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000007340 Hordeum vulgare Nutrition 0.000 title claims abstract description 87
- 238000000855 fermentation Methods 0.000 title claims abstract description 74
- 230000004151 fermentation Effects 0.000 title claims abstract description 74
- 239000000284 extract Substances 0.000 title claims abstract description 38
- 240000005979 Hordeum vulgare Species 0.000 title description 2
- 241000209219 Hordeum Species 0.000 claims abstract description 85
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 17
- 241000191963 Staphylococcus epidermidis Species 0.000 claims abstract description 12
- 230000001105 regulatory effect Effects 0.000 claims abstract description 12
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 9
- 244000005714 skin microbiome Species 0.000 claims abstract description 9
- 239000000706 filtrate Substances 0.000 claims description 33
- 239000006228 supernatant Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 7
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 7
- 229960005323 phenoxyethanol Drugs 0.000 claims description 7
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 abstract description 16
- 210000002950 fibroblast Anatomy 0.000 abstract description 9
- 230000035755 proliferation Effects 0.000 abstract description 9
- 210000001339 epidermal cell Anatomy 0.000 abstract description 6
- 230000002500 effect on skin Effects 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 50
- 239000000047 product Substances 0.000 description 32
- 241000282414 Homo sapiens Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036559 skin health Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000013550 pizza Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229940031575 hydroxyethyl urea Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000004347 surface barrier Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
- C12N1/185—Saccharomyces isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/85—Saccharomyces
- C12R2001/865—Saccharomyces cerevisiae
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Cosmetics (AREA)
Abstract
本发明属于植物提取领域及日化领域,具体涉及青稞发酵提取物的应用。青稞经过酿酒酵母的发酵,发酵液离心过滤后得到的青稞发酵提取物,能够降低金黄色葡萄球菌/表皮葡萄球菌的比值、促进真皮成纤维细胞和表皮细胞增殖,从而实现调节皮肤菌群、维持和/或修复皮肤表面微生态,以及修复老化的皮肤。因此,青稞发酵提取物可用作制备皮肤外用剂,作为修复老化皮肤、改善皮肤表面微生态的活性成分。
Description
技术领域
本发明属于植物提取领域及日化领域,具体涉及青稞发酵提取物的应用。
背景技术
人皮肤成纤维细胞是皮肤真皮网织层中最重要的细胞,是皮肤衰老和细胞受损后的主要修复细胞之一。它不但能够促进表皮细胞的迁移、增殖和分化,还能分泌大量的胶原蛋白、弹性纤维蛋白及多种细胞修复因子,具有强大的自我更新能力,从而修复老化的皮肤。
人体皮肤表面和肠道中贮存着大量的微生物,自出生开始就伴随着我们,与人类为共生关系。其中,皮肤表面菌群或表面微生态,作为人体皮肤物理屏障更外层的一种重要生物屏障,对皮肤的健康状态有着重要作用。表面菌群根据不同的性别、年龄、外部环境等具有明显的个体差异,而表面菌群的失衡,特别是某些条件致病菌在表面菌群中的比例异常时,往往会引起各种肌肤疾病。表皮葡萄球菌S.e(Staphylococcus epidermidis;S.epidermidis)是人体皮肤的常驻菌之一,而金黄色葡萄球菌S.a(Staphylococcusaureus;S.aureus)比例异常时,则会破坏皮肤表面屏障,或者引起炎症等皮肤问题。
微生物是维持皮肤微生态平衡的重要成员。皮肤微生物以细菌为主,皮肤微生物可分为常驻菌和暂驻菌。常驻菌群与皮肤健康息息相关,它们定植于皮肤表面形成生物膜,一方面具有占位保护效应,作为物理屏障阻挡外源性致病菌的入侵;另一方面还可通过产生抗菌肽而抑制或杀灭病原菌,主要包括表皮葡萄球菌、微球菌、棒状杆菌、丙酸杆菌、不动杆菌及马拉色菌等。暂驻菌包括金黄色葡萄球菌S.aureus、链球菌、大肠杆菌及白念珠菌等,它们是引起皮肤感染的主要病原菌。
S.aureus是皮肤常见感染细菌之一。研究表明特异性皮炎患者(AD)患者皮损处S.aureus定植率达78%。对已有研究进行梳理发现,AD皮肤表面微生态处于失衡状态,这不仅表现为S.aureus数量的显著升高,更加体现在其他皮肤常驻菌相对丰度、菌群多样性及丰富度的减少。
《皮炎湿疹患者皮肤菌群的测定及其临床研究》(孟华,《临床医药文献电子杂志》,2018)的报道,皮肤菌群测定显示:观察组(各型皮炎湿疹患者40例)金黄色葡萄球菌(57.50%)、表皮葡萄球菌(32.50%),显著高于对照组(健康人40例)中金黄色葡萄球菌(0%)和表皮葡萄球菌(7.50%)。根据报道计算可知,病患皮肤中S.a/S.e的比值为1.77,而健康皮肤中S.a/S.e的比值为0%。
因此,如果能够促进人皮肤成纤维细胞的增殖,则可以延缓和修复皮肤衰老,或者降低金黄色葡萄球菌/表皮葡萄球菌的比值即S.a/S.e值,可以改善皮肤表面菌群和表面微生态,促进皮肤健康。若单一活性物质能够同时解决上述问题,会有很大的应用价值。
青稞(拉丁名Hordeum vulgare L.var.nudum hook.f.,别称Highland Barley、Hulless Barley)属于禾本科大麦属,在植物上属于栽培大麦的变种,主要种植于青藏高原地区,并且是唯一可在4200m以上种植的作物。我国青稞品种资源丰富,不同颜色、不同形状的品种多达上千种。青稞符合“三高两低”(高蛋白质、高纤维素、高维生素、低糖、低脂)的饮食结构,含有丰富的线性非淀粉多糖β-葡聚糖(谷类粮食中最高)、酚类化合物、维生素以及矿物质等营养活性成分。
酵母是与人类生活息息相关的一种微生物,至少在3000年前人类就开始利用酵母的自然发酵过程生产酒类,而最早的有关发酵护肤品的工艺是马王堆汉墓中出土的“醪利”中,而目前酿酒酵母(Saccharomyces cerevisiae;缩写S.cerevisiae)和各种生物发酵技术及产物也广泛应用到护肤品中,酵母提取物成为一种热门的功效护肤原料。
而目前还未见有将青稞经过发酵后的提取物用作皮肤外用剂的报道,也未见青稞发酵提取物用以改善皮肤表面微生态或者修复老化皮肤的报道。
发明内容
本发明旨在提供青稞发酵提取物在制备皮肤外用剂方面的应用。
本发明还提供了一种皮肤外用剂,含有青稞发酵提取物。
技术方案为:青稞发酵提取物用于制备皮肤外用剂。具体的,所述的青稞发酵提取物作为维持和/或修复皮肤表面微生态的活性成分;或者作为修复老化的皮肤的活性成分。
所述的青稞发酵提取物通过调节皮肤菌群来维持和/或修复皮肤表面微生态;所述的青稞发酵提取物通过促进皮肤细胞增殖修复老化的皮肤。
进一步,所述青稞发酵提取物降低金黄色葡萄球菌/表皮葡萄球菌的比值来调节皮肤菌群,或者促进真皮成纤维细胞和/或表皮细胞增殖。
青稞发酵提取物可以通过液体发酵方法获得,将青稞粉碎后与水混合,用酵母进行发酵。优选的,所述酵母为酿酒酵母。发酵液经过离心取上清液、过滤后取滤液即得到青稞发酵提取物。还可以进行稀释、浓缩,或者制成浸膏或干粉。
青稞发酵提取物的制备方法为:(1)青稞粉碎后与水混合,接入酵母,在15~30℃、150~250rpm条件下恒温培养36-72小时进行液体发酵;(2)发酵液在4~10℃、1000~8000rpm条件下离心10~60min,取上清液;(3)上清液调节pH至5.0~7.0,80~90℃加热30~60min后,1000~8000rpm离心10~30min,取上清液;(4)上清液用孔径0.05~0.22μm滤膜在1~5bar压力下过滤,取发酵滤液。
优选的,青稞为带麸皮的青稞籽粒,产自泛喜马拉雅地区的西藏拉萨市。所述含有青稞粉的培养基中,青稞粉含量为1wt%~5wt%,余量为水。所述的酵母为酿酒酵母(Saccharomyces cerevisiae;S.cerevisiae)。优选的,青稞粉碎至20~200目颗粒。优选的,发酵温度为26~30℃。
所述的青稞发酵提取物为青稞发酵滤液,或者由所述青稞发酵滤液制得的稀释液、浓缩液、浸膏或干燥物。
一种皮肤外用剂,含有青稞发酵提取物;所述的青稞发酵提取物作为维持和/或修复皮肤表面微生态的活性成分,或者作为修复老化的皮肤的活性成分。
以干物质含量计,青稞发酵提取物的含量为0.001wt%~5wt%;优选的,以干物质含量计,青稞发酵提取物的含量为0.005wt%~5wt%。更优选的,以干物质含量计,青稞发酵提取物的含量为0.01wt%~2wt%。
优选的,所述皮肤外用剂还含有以下成分中的至少一种:补水活性成分、美白活性成分、保湿活性成分、抗氧化活性成分、抗皱活性成分、祛斑活性成分、消痘活性成分、防晒活性成分、祛粉刺/痤疮活性成分、祛头屑活性成分、抗过敏活性成分或者皮脂腺抑制活性成分。
皮肤外用剂指以涂抹、喷洒或者其它类似方法,散布于人体表面的任何部位,以达到清洁、保养、美容、修饰、改变外观或者修正人体气味,保持良好状态的产品。皮肤外用剂可以是起到清洁、护理、美化或保养等作用的基础化妆品、面部化妆品、头部护理品、身体护理品。
优选的,上述皮肤外用剂为化妆品。
一种皮肤外用剂原料,以青稞发酵提取物为活性成分,并含有4wt%~10wt%丁二醇、0.45wt%~0.72wt%苯氧乙醇和0.05wt%~0.08wt%乙基己基甘油。
所述皮肤外用剂原料的制备方法为:(1)青稞经过液体发酵的发酵液在4~10℃、1000~8000rpm条件下离心10~60min,取上清液;(2)上清液调节pH至5.0~7.0,80~90℃加热30~60min后,1000~8000rpm离心10~30min,取上清液;(3)上清液用孔径0.05~0.22μm滤膜在1~5bar压力下过滤,取发酵滤液;(4)发酵滤液中依次加入丁二醇、苯氧乙醇和乙基己基甘油。
一种化妆水,其组分包括:以固含量计0.01wt%~3wt%的青稞发酵提取物,以及:0~5wt%甘油、2wt%~5wt%丁二醇、0~4wt%羟乙基脲、0~2wt%烟酰胺、0~0.02wt%透明质酸钠或透明质酸钾、0~0.2wt%甘草酸二钾、0~0.2wt%尿囊素、0~0.2wt%羟苯甲酯、0~0.1wt%EDTA二钠、0~0.5wt%苯氧乙醇、0~0.1wt%乙基己基甘油、0~可接受剂量香精,余量为去离子水。
本发明的有益效果在于,将青稞用酿酒酵母发酵,发酵液离心过滤后得到的青稞发酵提取物,能够降低金黄色葡萄球菌/表皮葡萄球菌的比值、促进真皮成纤维细胞和表皮细胞增殖,从而实现调节皮肤菌群、维持和/或修复皮肤表面微生态,维持皮肤健康以及修复老化的皮肤。因此,青稞发酵提取物可以用作皮肤外用剂,尤其是化妆品的活性成分;可以用于制备皮肤外用剂,尤其是调节皮肤菌群,维持修复皮肤表面微生态及修复老化皮肤的皮肤外用剂,具有良好的应用前景。
附图说明
图1为青稞发酵产物滤液对表面菌群S.a/S.e比值的影响。
图2为青稞发酵产物滤液对Fibroblast的生长影响。
图3为青稞发酵产物滤液对HaCaT的生长影响如图3所示。
具体实施方式
实施例1制备青稞发酵产物滤液
本发酵产物的基质原料为青稞,产自泛喜马拉雅地区的西藏拉萨市。用去离子水清洗包含麸皮的青稞籽粒,晾干后打粉机打粉,过20-100目筛获得青稞粉。将青稞粉与去离子水混合,发酵培养基/培养液中青稞粉的含量为4wt%;高温高压灭菌后冷却用酿酒酵母菌(Saccharomyces cerevisiae)在26~30℃、150~250rpm条件下发酵48小时。
青稞发酵滤液的制备:
(1)发酵产物在4~10℃、6000rpm条件下离心10~30min,取上清液;
(2)调节pH至5.0~7.0,80~90℃水浴30~60min后,4000rpm离心30min,取上清液;
(3)选用孔径为0.05、0.10或0.22μm的滤膜,滤膜预浸泡于75%(v/v)乙醇中;过滤滤器及器材用75%(v/v)乙醇清洗,70℃烘箱烘干后使用;
(5)膜过滤装置先使用0.5%NaOH水溶液循环和浸泡5~10min后,改用0.5%NaHSO3水溶液循环或浸泡5~10min,然后用去离子水清洗。将膜片装入设备后,接入灭菌水清洗后将水排空;
(6)接入步骤(2)中的上清液进行过滤,通过调节压力(≤5bar)来控制过滤速度(1.0-2.0L/h),过滤后的发酵滤液装在无菌容器中储存。
所得到的青稞发酵滤液中,干物质含量为1.5wt%。
实施例2青稞发酵提取物对表面菌群的影响
(一)实验材料
1.实验菌种
表皮葡萄球菌S.e(Staphylococcus epidermidis)、金黄色葡萄球菌S.a(Staphylococcus aureus)。
2.培养基
LB培养基:0.5%酵母粉,1.0%胰蛋白胨,1.0%NaCl,余量为水,所述百分比为质量百分比。121℃,20min高温高压灭菌后冷却备用。
3.样品信息
空白样品(Control):无菌生理盐水:0.9%NaCl,余量为水,所述百分比为质量百分比。121℃,20min高温高压灭菌后冷却备用。
实验样品:实施例1所获得的青稞发酵产物滤液,其中固含量为1.5wt%。
(二)实验步骤
1.将保藏的S.a和S.e(单菌落或冻存管菌液)接入无菌LB液体培养基中活化复苏(1CFU/4mL或50μL/mL);摇床37℃,150-250rpm培养8-24小时;LB培养基可维持S.a和S.e的正常生长代谢,培养16h后,两者均可达到生长稳定期;
2.2000~6000rpm离心移除培养基,生理盐水逐步稀释重悬菌液(C0)至1/2C0、1/4C0和1/8C0,测定各浓度两种重悬菌液的OD600,确定两者的菌体浓度比值,并根据各自的OD600值按比例稀释,重新获得等OD600菌悬液。
3.利用S.a和S.e的等OD菌悬液,分别加入不同浓度的青稞发酵产物滤液到无菌LB培养基中,获得质量百分数为0.015%、0.15%、0.3%和0.45%的青稞发酵滤液(干重)培养基,测试体系总体积4mL,并按体积比0.2%~2%接种。培养8-24小时后,采用比浊法通过测定吸光值OD600表示微生物的生物量。p<0.05视为显著性差异,*p<0.05,**p<0.01,***p<0.001。
不同浓度青稞发酵产物滤液品(干重含量)对S.a/S.e的调节作用如图1所示。实验结果显示,青稞发酵产物滤液对S.a/S.e比值产生明显影响,具有选择性影响S.a和S.e生长的作用,能够降低S.a/S.e值,帮助人体表面微生物菌群的稳态维持,或对失衡的皮肤表面微生态进行调整修复。
如图1,四种浓度下,S.a/S.e的值相比于空白对照的1.660,分别下降3.55%、29.51%、36.56%和39.16%。这表明青稞发酵产物能显著地降低生物量比值,并且随着浓度的增加而逐渐降低;青稞发酵产物具有将皮肤表面微生物菌群中S.a和S.e的比例调整至更加健康状态的潜力。
实施例3青稞发酵产物的细胞增殖作用
(一)实验材料
细胞:真皮成纤维细胞Fibroblast、人永生化表皮细胞HaCaT。
实验样品:青稞发酵产物滤液用去离子水配制成不同浓度溶液,在不同细胞生长所需的无血清DMEM或MEM培养基中加入各浓度的青稞发酵产物滤液,使培养基中青稞发酵产物滤液干物质含量为0.015%、0.075%和0.15%,所述百分比为质量百分比。
(二)实验方法
青稞发酵产物滤液用去离子水配制成不同浓度溶液,加入到人成纤维细胞培养液中,以不含样品的去离子水为空白对照,培养48小时后,用MTT法对细胞染色后,用酶标仪测定550nm处吸光度,空白对照的增殖率为100%,参比空白对照,评估对人成纤维细胞的增殖作用。p<0.05视为显著性差异,*p<0.05,**p<0.01。无血清培养基中青稞发酵产物滤液的干物质含量分别为0.015%、0.075%和0.15%,所述百分比为质量百分比。
(三)实验结果
青稞发酵产物滤液对Fibroblast的生长影响如图2所示,对HaCaT的生长影响如图3所示。
如图2、3结果所示,不同浓度青稞发酵产物滤液(干重含量)均对成纤维细胞和表皮细胞有增殖作用,并且随着浓度的增加,对成纤维细胞的生长促进作用逐渐增强,0.15%青稞发酵产物滤液能够使成纤维细胞和HaCaT的最高细胞活力分别达到154.1%和110.10%。
因此,青稞发酵产物滤液即青稞发酵提取物能够促进人皮肤细胞增殖,从而修复老化的皮肤,具有抗衰老的效果。
实施例4青稞发酵产物滤液用于制备化妆品/皮肤外用剂
处理工艺为:实施例1所得到的过滤液中先后加入丁二醇、苯氧乙醇和乙基己基甘油,充分搅拌使之混合均匀,混合后的样品中,丁二醇含量为4wt%~10wt%,苯氧乙醇含量为0.45wt%~0.72wt%,乙基己基甘油含量为0.05wt%~0.08wt%。最后将样品室温或者4℃避光保存。待生产时,按照本领域常规的化妆水/精华液/乳液/霜的制备方法添加。上述配方产物也可以直接用作化妆水。
实施例5含青稞发酵提取物的化妆水
取实施例1的青稞发酵产物滤液,用于制备具有调节皮肤微生态菌群作用的化妆水,按照本领域常规的化妆水的制备方法,化妆水所含的组分如表1所示:
表1
Claims (4)
1.青稞发酵提取物在制备具有调节皮肤菌群、维持和/或修复皮肤表面微生态的功能皮肤外用剂方面的应用;其特征在于,青稞发酵提取物的制备方法为:(1)青稞粉碎后与水混合,接入酵母,在15~30℃、150~250rpm条件下恒温培养36-72小时进行液体发酵;(2)发酵液在4~10℃、1000~8000rpm条件下离心10~60min,取上清液;(3)上清液调节pH至5.0~7.0,80~90℃加热30~60min后,1000~8000rpm离心10~30min,取上清液; (4)上清液用孔径0.05~0.22μm滤膜在1~5bar压力下过滤,取发酵滤液。
2.权利要求1所述的应用,其特征在于,所述青稞发酵提取物降低金黄色葡萄球菌/表皮葡萄球菌的比值来调节皮肤菌群,以及维持和/或修复皮肤表面微生态。
3.权利要求1或2所述的应用,其特征在于,以固含量计,所述的皮肤外用剂中,青稞发酵提取物的含量为0.005wt%~5wt%。
4.一种皮肤外用剂原料,其特征在于,以青稞发酵提取物为活性成分,并含有4wt%~10wt%丁二醇、0.45 wt%~ 0.72wt%苯氧乙醇和0.05 wt%~ 0.08 wt%乙基己基甘油,其制备方法步骤包括:(1) 青稞经过液体发酵的发酵液在4~10℃、1000~8000rpm条件下离心,取上清液;(2) 上清液调节pH至5.0~7.0,80~90℃加热30~60min后,1000~8000rpm离心,取上清液; (3) 上清液用孔径0.05~0.22μm滤膜在1~5bar压力下过滤,取发酵滤液;(4) 发酵滤液中加入依次加入丁二醇、苯氧乙醇和乙基己基甘油。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910780847.9A CN112402334B (zh) | 2019-08-22 | 2019-08-22 | 青稞发酵提取物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910780847.9A CN112402334B (zh) | 2019-08-22 | 2019-08-22 | 青稞发酵提取物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112402334A CN112402334A (zh) | 2021-02-26 |
CN112402334B true CN112402334B (zh) | 2024-01-05 |
Family
ID=74780239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910780847.9A Active CN112402334B (zh) | 2019-08-22 | 2019-08-22 | 青稞发酵提取物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112402334B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114404344B (zh) * | 2022-01-28 | 2023-04-25 | 北京工商大学 | 酵母菌/大麦籽发酵产物,含其产品及其制备方法和应用 |
JP7307833B1 (ja) | 2022-03-17 | 2023-07-12 | 株式会社ナリス化粧品 | 核形態異常改善剤 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107308073A (zh) * | 2017-06-26 | 2017-11-03 | 上海应用技术大学 | 一种青稞发酵原浆及制备方法和应用 |
CN109010095A (zh) * | 2018-09-20 | 2018-12-18 | 黄犟兵 | 一种用于海藻纤维面膜布的面膜液及其制备方法 |
CN109875940A (zh) * | 2019-04-03 | 2019-06-14 | 成都肌本演绎美丽科技有限公司 | 一种含β-葡聚糖精华液的制备方法及皮肤屏障修复应用 |
-
2019
- 2019-08-22 CN CN201910780847.9A patent/CN112402334B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107308073A (zh) * | 2017-06-26 | 2017-11-03 | 上海应用技术大学 | 一种青稞发酵原浆及制备方法和应用 |
CN109010095A (zh) * | 2018-09-20 | 2018-12-18 | 黄犟兵 | 一种用于海藻纤维面膜布的面膜液及其制备方法 |
CN109875940A (zh) * | 2019-04-03 | 2019-06-14 | 成都肌本演绎美丽科技有限公司 | 一种含β-葡聚糖精华液的制备方法及皮肤屏障修复应用 |
Non-Patent Citations (2)
Title |
---|
Skin Health Promotion Effects of Natural Beta-Glucan Derived from Cereals and Microorganisms: A Review;Bin Du等;PHYTOTHERAPY RESEARCH;第1-8页 * |
β-葡聚糖在化妆品中的应用;严明强等;香料香精化妆品(第6期);第31页摘要,第33页左栏第4段,第34页左栏第2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN112402334A (zh) | 2021-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112402333B (zh) | 红米发酵提取物在制备化妆品中的应用 | |
CN110638740A (zh) | 一种具有调节皮肤微生态的组合物及其应用 | |
CN109893487B (zh) | 一种大米玫瑰发酵原浆及其制备方法与应用 | |
CN115554226B (zh) | 一种多重菌株发酵滤液及其制备方法和应用 | |
CN106726949B (zh) | 一种葡萄籽发酵原浆化妆品及其制备方法与应用 | |
CN112402334B (zh) | 青稞发酵提取物的应用 | |
CN109939059B (zh) | 一种稻胚芽五菌发酵缓释化妆品及其制备方法和应用 | |
JP2016074647A (ja) | 保湿効果を有する乳酸菌米発酵物 | |
TWI388343B (zh) | 含有經發酵及酵素作用綠豆萃取液之抗皮膚衰老化妝品成分及其使用方法 | |
CN111904909B (zh) | 一种含有玫瑰发酵液的去屑头皮精华及其制备方法 | |
CN111904908B (zh) | 一种含有玫瑰发酵液的精华液及其制备方法 | |
CN113398045A (zh) | 一种抗衰老、舒缓的芦荟发酵物及其制备方法与应用 | |
CN116376731B (zh) | 一种异常威克汉姆酵母菌在制备青刺果提取物中的应用 | |
CN115927128B (zh) | 一种透明颤菌发酵产物及其制备方法与应用 | |
CN111358735A (zh) | 一种乳酸杆菌大米发酵产物及其制备方法 | |
CN114404344B (zh) | 酵母菌/大麦籽发酵产物,含其产品及其制备方法和应用 | |
CN113440455B (zh) | 青稞发酵液的应用 | |
CN112522150B (zh) | 一种能长效祛屑止痒的淘米水植物发酵产品及制备方法 | |
KR20200054590A (ko) | 미강 발효 고형분을 유효성분으로 함유한 피부 장벽 강화용 화장료 조성물 | |
CN111789801B (zh) | 一种含有玫瑰发酵液的保湿沐浴露及其制备方法 | |
KR101750619B1 (ko) | 여주와 어성초를 이용한 삼투압 효소 발효물의 제조방법, 이로부터 제조된 발효물 및 이를 포함하는 화장료, 식품 또는 약학 조성물 | |
CN112402455B (zh) | 牦牛奶发酵提取物的应用 | |
CN114317617A (zh) | 具有抗皱功效的三重益生菌发酵复合物制备方法及其应用 | |
KR20180026923A (ko) | 보이차 추출물을 함유하는 마스크팩용 바이오셀룰로오스 시트 및 이의 제조방법 | |
CN111671706A (zh) | 一种红米发酵滤液及其制备方法与在制备化妆品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 201403 Shanghai City, Fengxian District Lifenglu No. 12 Patentee after: Shanghai Natural Hall Group Co.,Ltd. Address before: 201403 Shanghai City, Fengxian District Lifenglu No. 12 Patentee before: JALA Group Co. |
|
CP03 | Change of name, title or address |